TY - JOUR
T1 - Evaluating the effectiveness of joint specialist case conferences in improving diabetes control in patients with schizophrenia on clozapine
AU - Zheng, Yu
AU - Meyerowitz-Katz, Gideon
AU - Bramwell, Sian
AU - Jayaballa, Rajini
AU - Assur, Yolinda
AU - Vasani, Deepali
AU - Ganapathy, Ramanathan
AU - Maberly, Glen
AU - Brakoulias, Vlasios
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Clozapine treatment for schizophrenia is typically long-term and is associated with a high rate of diabetes. Mental health and diabetes specialist teams at a local hospital in Australia have undertaken a series of joint specialist case conferences (JSCCs) where the diabetes team works with the psychiatry team to improve diabetes management. In this retrospective cohort study conducted between 2013 and 2018, we found that glycemic control in clozapine clinics linked with JSCCs was improved significantly compared with that in the non-JSCC clinics. In the non-JSCC clozapine clinics (control), the poor glycemic control rates stayed at a similar level: 23% in 2013 and 24% in 2018. In contrast, whereas the control patients' poor glycemic rate in JSCC clozapine clinics in 2013 was 24%, it decreased markedly in 2018 to 13%. This study indicates that JSCCs can improve diabetes outcomes in a group of patients with severe mental illness.
AB - Clozapine treatment for schizophrenia is typically long-term and is associated with a high rate of diabetes. Mental health and diabetes specialist teams at a local hospital in Australia have undertaken a series of joint specialist case conferences (JSCCs) where the diabetes team works with the psychiatry team to improve diabetes management. In this retrospective cohort study conducted between 2013 and 2018, we found that glycemic control in clozapine clinics linked with JSCCs was improved significantly compared with that in the non-JSCC clinics. In the non-JSCC clozapine clinics (control), the poor glycemic control rates stayed at a similar level: 23% in 2013 and 24% in 2018. In contrast, whereas the control patients' poor glycemic rate in JSCC clozapine clinics in 2013 was 24%, it decreased markedly in 2018 to 13%. This study indicates that JSCCs can improve diabetes outcomes in a group of patients with severe mental illness.
KW - Clozapine
KW - psychiatry
KW - schizophrenia
KW - diabetes
UR - https://hdl.handle.net/1959.7/uws:73128
UR - http://www.scopus.com/inward/record.url?scp=85148963953&partnerID=8YFLogxK
U2 - 10.1097/NMD.0000000000001590
DO - 10.1097/NMD.0000000000001590
M3 - Article
SN - 0022-3018
VL - 211
SP - 221
EP - 225
JO - Journal of Nervous and Mental Disease
JF - Journal of Nervous and Mental Disease
IS - 3
ER -
